سلوفاكيا - السلوفاكية - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sandoz pharmaceuticals d.d., slovinsko - oxykodón a naloxón - 65 - analgetica - anodyna

سلوفاكيا - السلوفاكية - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sandoz pharmaceuticals d.d., slovinsko - oxykodón a naloxón - 65 - analgetica - anodyna

سلوفاكيا - السلوفاكية - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sandoz pharmaceuticals d.d., slovinsko - oxykodón a naloxón - 65 - analgetica - anodyna

سلوفاكيا - السلوفاكية - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sandoz pharmaceuticals d.d., slovinsko - oxykodón a naloxón - 65 - analgetica - anodyna

سلوفاكيا - السلوفاكية - ŠÚKL (Štátny ústav pre kontrolu liečiv)

fresenius kabi s.r.o., Česká republika - lenalidomid - 59 - immunopraeparata

سلوفاكيا - السلوفاكية - ŠÚKL (Štátny ústav pre kontrolu liečiv)

fresenius kabi s.r.o., Česká republika - lenalidomid - 59 - immunopraeparata

سلوفاكيا - السلوفاكية - ŠÚKL (Štátny ústav pre kontrolu liečiv)

fresenius kabi s.r.o., Česká republika - lenalidomid - 59 - immunopraeparata

الاتحاد الأوروبي - السلوفاكية - EMA (European Medicines Agency)

les laboratoires servier - trifluridine, tipiracil hydrochlorid - kolorektálne novotvary - antineoplastické činidlá - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

الاتحاد الأوروبي - السلوفاكية - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir - hiv infekcie - antivirotiká na systémové použitie - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.

سلوفاكيا - السلوفاكية - ŠÚKL (Štátny ústav pre kontrolu liečiv)

gedeon richter plc., maďarsko - haloperidol - 68 - antipsychotica (neuroleptica)